| P2093 | author name string | W E Gillanders | |
| | D C Linehan | |
| | W G Hawkins | |
| | P Goedegebuure | |
| | A Wang-Gillam | |
| | B A Belt | |
| | J B Mitchem | |
| | M C B Tan | |
| | M R Porembka | |
| P2860 | cites work | Development of bisphosphonates | Q21195188 |
| | CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer | Q24318416 |
| | VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche | Q24600542 |
| | Modes of resistance to anti-angiogenic therapy | Q24608005 |
| | S100 chemokines mediate bookmarking of premetastatic niches | Q24630751 |
| | Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 |
| | Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein | Q24641894 |
| | The role of NKT cells in tumor immunity | Q24648939 |
| | Inflammation and cancer | Q24649640 |
| | Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer | Q24651062 |
| | Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells | Q24658240 |
| | B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma | Q24676809 |
| | Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 |
| | Cancer statistics, 2010 | Q27860525 |
| | Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 |
| | Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 |
| | PD-1 and its ligands in tolerance and immunity | Q28131650 |
| | Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases | Q28131652 |
| | The tumor microenvironment and its role in promoting tumor growth | Q36946019 |
| | Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells | Q36969858 |
| | Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. | Q36982546 |
| | Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity | Q36996588 |
| | Creating immune privilege: active local suppression that benefits friends, but protects foes. | Q37026641 |
| | Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. | Q37104501 |
| | Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma | Q37106218 |
| | Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. | Q37118160 |
| | Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives | Q37118164 |
| | High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma | Q37222638 |
| | Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4 | Q37232937 |
| | Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. | Q37273173 |
| | Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. | Q37327260 |
| | Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. | Q37338140 |
| | Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. | Q37340505 |
| | Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? | Q37393423 |
| | An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. | Q37486791 |
| | The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer | Q37487325 |
| | Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation | Q37594369 |
| | Novel agents for the treatment of adenocarcinoma of the pancreas | Q37614590 |
| | Immune infiltration in human tumors: a prognostic factor that should not be ignored | Q37641059 |
| | Myeloid-derived suppressor cell heterogeneity and subset definition. | Q37695457 |
| | Antigen specificity of immune suppression by myeloid-derived suppressor cells | Q37864462 |
| | Mechanisms by which Activated Macrophages Inhibit Lymphocyte Responses | Q37991335 |
| | Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial | Q38391782 |
| | The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis | Q39567775 |
| | 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity | Q39715226 |
| | Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. | Q39770285 |
| | Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. | Q39901596 |
| | New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine | Q39947732 |
| | Equilibrium between host and cancer caused by effector T cells killing tumor stroma | Q40006201 |
| | Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics | Q40011425 |
| | Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity | Q40013431 |
| | Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma | Q40017876 |
| | Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice | Q40045304 |
| | Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head | Q40068712 |
| | A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model | Q40099109 |
| | Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response | Q80582229 |
| | Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses | Q80798275 |
| | Dynamics of the immune reaction to pancreatic cancer from inception to invasion | Q81381605 |
| | CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis | Q81386279 |
| | Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations | Q81540982 |
| | Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor | Q81555396 |
| | CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells | Q81598364 |
| | Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer | Q84156945 |
| | Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | Q84256128 |
| | Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma | Q84425427 |
| | Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species | Q73719137 |
| | Systemic and local immunosuppression in pancreatic cancer patients | Q73745122 |
| | Clinical significance of defective dendritic cell differentiation in cancer | Q73803370 |
| | Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells | Q73939950 |
| | Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients | Q75275280 |
| | Immunological escape mechanisms in pancreatic carcinoma | Q78027682 |
| | Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients | Q79323463 |
| | 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience | Q79369906 |
| | Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion | Q79441078 |
| | Systemic immune dysfunction in pancreatic cancer patients | Q79603775 |
| | CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers | Q79674004 |
| | Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients | Q80480802 |
| | Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 |
| | Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation | Q28141319 |
| | The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils | Q28269488 |
| | Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis | Q28275735 |
| | The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase | Q28507440 |
| | Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function | Q28510096 |
| | Monocyte and macrophage heterogeneity | Q29547438 |
| | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 |
| | Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 |
| | Regulation of immune responses by L-arginine metabolism | Q29614284 |
| | Subsets of myeloid-derived suppressor cells in tumor-bearing mice | Q29614297 |
| | The role of myeloid cells in the promotion of tumour angiogenesis | Q29614299 |
| | Distinct role of macrophages in different tumor microenvironments | Q29614304 |
| | IDO expression by dendritic cells: tolerance and tryptophan catabolism | Q29614752 |
| | Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 |
| | An essential role for Scurfin in CD4+CD25+ T regulatory cells | Q29618395 |
| | Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 |
| | IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity | Q29620119 |
| | Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 |
| | Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). | Q30781823 |
| | Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. | Q31034362 |
| | Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity | Q33186765 |
| | A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells | Q33335471 |
| | Modulators of arginine metabolism support cancer immunosurveillance | Q33398779 |
| | Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells | Q33567728 |
| | Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine | Q33584867 |
| | All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia | Q33604359 |
| | Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. | Q33705930 |
| | Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells | Q33707270 |
| | Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. | Q33733198 |
| | Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. | Q33763653 |
| | Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor | Q33805313 |
| | Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells | Q33873201 |
| | Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation | Q33887648 |
| | Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes | Q33978763 |
| | Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells | Q34072679 |
| | Targeting immune suppressing myeloid-derived suppressor cells in oncology. | Q34082067 |
| | HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment | Q34243443 |
| | All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. | Q36703036 |
| | Reversal of tumor-mediated immunosuppression | Q36718968 |
| | The adaptive immunologic microenvironment in colorectal cancer: a novel perspective | Q36749070 |
| | New developments of aminobisphosphonates: the double face of Janus. | Q36860167 |
| | Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways | Q36927973 |
| | The metastatic niche: adapting the foreign soil | Q36928869 |
| | Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells | Q40141520 |
| | Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer | Q40314081 |
| | Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression | Q40338318 |
| | Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis | Q40339595 |
| | Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity | Q40372686 |
| | High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells | Q40519826 |
| | Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. | Q40605195 |
| | Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. | Q40758963 |
| | Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone | Q41826343 |
| | Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer | Q42183073 |
| | The terminology issue for myeloid-derived suppressor cells | Q42425163 |
| | Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. | Q42445950 |
| | Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients | Q42482401 |
| | Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients | Q42516923 |
| | In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site | Q42728755 |
| | Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells. | Q43001771 |
| | Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells | Q43582877 |
| | Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. | Q43640348 |
| | IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice | Q44259082 |
| | Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma | Q44427230 |
| | Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. | Q44675420 |
| | Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice | Q44946383 |
| | Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses | Q45020410 |
| | Tumor-induced immune dysfunction: the macrophage connection. | Q45113707 |
| | Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity | Q45862329 |
| | Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties | Q46064310 |
| | Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients | Q46093084 |
| | Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion | Q46440292 |
| | Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study | Q46466364 |
| | Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head | Q46473461 |
| | Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. | Q46529900 |
| | Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). | Q46672853 |
| | Cancer immunology. Cancer's bulwark against immune attack: MDS cells | Q46813671 |
| | CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress | Q46925832 |
| | Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. | Q51803685 |
| | Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. | Q51982680 |
| | High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. | Q51987499 |
| | Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. | Q54287306 |
| | Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. | Q54692947 |
| | Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma | Q56904280 |
| | Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host | Q57054792 |
| | Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma | Q59245171 |
| | Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis | Q59276609 |
| | Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 |
| | Early hematopoietic events during tumor growth in mice | Q68794382 |
| | Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors | Q70019545 |
| | Suppressor cells in immunodepressed bladder and prostate cancer patients | Q70532777 |
| | Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor | Q70863242 |
| | Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells | Q71607047 |
| | Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells | Q73202053 |
| | Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer | Q73311980 |
| | Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells | Q34312635 |
| | Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis | Q34418159 |
| | A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). | Q34465280 |
| | Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. | Q34504134 |
| | Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity | Q34505678 |
| | A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer | Q34546440 |
| | Mast cells are essential intermediaries in regulatory T-cell tolerance | Q34559099 |
| | Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor | Q34577892 |
| | Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial | Q34602771 |
| | Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis | Q34616787 |
| | Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells | Q34723007 |
| | Modulation of the antitumor immune response by complement | Q34838919 |
| | Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells | Q35052425 |
| | All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients | Q35062106 |
| | Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression | Q35478848 |
| | Derangement of immune responses by myeloid suppressor cells | Q35573513 |
| | The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity | Q35750663 |
| | Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone | Q35956822 |
| | Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 |
| | Immunotherapy for pancreatic cancer - science driving clinical progress | Q36133140 |
| | MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis | Q36229458 |
| | CD25+ CD4+ regulatory T-cells in cancer | Q36232697 |
| | Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression | Q36259867 |
| | Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer | Q36260673 |
| | CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment | Q36306137 |
| | Myeloid derived suppressor cells in human diseases | Q36338349 |
| | Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function | Q36384598 |
| | Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients | Q36399737 |
| | Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation | Q36403539 |
| | Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma | Q36403544 |
| | Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. | Q36432026 |
| | Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis | Q36464443 |
| | Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity | Q36490747 |
| | Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response | Q36528201 |
| P433 | issue | 6 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 734-751 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Current Cancer Drug Targets | Q332547 |
| P1476 | title | Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer | |
| P478 | volume | 11 | |